Predictors and predictive performance of immune–inflammation indices for symptom severity in benign prostatic hyperplasia
Abstract
Although the relatively unchanging consequences of age and genetic factors significantly contribute to the development and progression of Benign Prostatic Hyperplasia (BPH), numerous modifiable factors play a role in preventing progression or alleviating symptoms. Identifying predictors of symptom severity and objective biomarkers is beneficial for effective management. This study aimed to determine the predictors of BPH symptom severity and assess the predictive performance of hematologically derived inflammatory markers in patients attending Dessie Comprehensive Specialized Hospital in Ethiopia. A cross-sectional study was conducted from August to October 2024. Data was collected through face-to-face interviews performed by well-trained health professionals using the KoboCollect application. STATA version 17 was utilized for statistical data analysis. Bivariable and multivariable logistic regression analyses were employed to identify predictors of BPH severity, with a p-value of 564.92 × 10³ (AOR = 2.97, 95% CI: 1.10-7.98), PII > 273.3 × 10⁶ (AOR = 2.46, 95% CI: 1.04-5.86), and NLR ≥ 1.368 (AOR = 2.87, 95% CI: 1.01-8.14)] were significantly associated with severe BPH symptoms (p-value < 0.05). In ROC analysis, SII exhibited the highest predictive performance for severe symptoms with an AUC of 0.736 (95% CI: 0.67, 0.801); optimal cut-off: 564.92 × 10³; specificity - 72%, sensitivity - 69%; PII demonstrated similar performance with an AUC of 0.729 (95% CI: 0.66, 0.796);…
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 232 participants or records.
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.